Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

SAN FRANCISCO (KGO) -- Bay Area researchers are fighting back against a particularly deadly form of cancer and they're doing it with a new generation of drugs. These drugs enlist the body's own immune ...

A biologist works on DNA extracted from cancer tissue in Oncompass Medicine's laboratory in Budapest, Hungary, June 2, 2021. Picture taken June 2, 2021. REUTERS/Bernadett Szabo (This is an excerpt of ...

In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

Chemotherapy has long been a cornerstone of cancer treatment, saving millions of lives. Stream Los Angeles News for free, 24/7, wherever you are. Drugmakers have poured billions of dollars into ...

When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non-small ...

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer usually caught in late stages.

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...